Krishnaswamy Raghavan
Overview
Explore the profile of Krishnaswamy Raghavan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
152
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tao L, Li J, Pinamanenni S, Raghavan K
Drug Dev Ind Pharm
. 2019 Feb;
45(5):819-825.
PMID: 30715959
BMS-830216 is a diprotic acid prodrug of two pK values (<2 and 6.8) with high apparent solubility at pH ≥ 7. At ∼ pH 4 solutions of BMS-830216 appear to...
2.
Narang A, Badawy S, Ye Q, Patel D, Vincent M, Raghavan K, et al.
Pharm Res
. 2015 Mar;
32(8):2579-94.
PMID: 25724158
Purpose: Precipitation of weakly basic drugs in intestinal fluids can affect oral drug absorption. In this study, the implications of self-association of brivanib alaninate in acidic aqueous solution, leading to...
3.
Li J, Zhao J, Tao L, Wang J, Waknis V, Pan D, et al.
Pharm Res
. 2014 Aug;
32(2):500-15.
PMID: 25107427
Purpose: To investigate the structural effect of polymeric excipients on the behavior of free volume of drug-polymer dispersions in relation to glass transition. Methods: Two drugs (indomethacin and ketoconazole) were...
4.
Mathias N, Xu Y, Patel D, Grass M, Caldwell B, Jager C, et al.
Mol Pharm
. 2013 Sep;
10(11):4063-73.
PMID: 24032349
Weak base therapeutic agents can show reduced absorption or large pharmacokinetic variability when coadministered with pH-modifying agents, or in achlorhydria disease states, due to reduced dissolution rate and/or solubility at...
5.
Wu Y, Levons J, Narang A, Raghavan K, Rao V
AAPS PharmSciTech
. 2011 Sep;
12(4):1248-63.
PMID: 21948318
Reactive impurities in pharmaceutical excipients could cause drug product instability, leading to decreased product performance, loss in potency, and/or formation of potentially toxic degradants. The levels of reactive impurities in...
6.
Li J, Yang B, Levons J, Pinnamaneni S, Raghavan K
J Pharm Sci
. 2011 Jun;
100(11):4907-21.
PMID: 21656767
Vitamin E D-alpha-tocopheryl polyethylene glycol succinate (TPGS) and polyethylene glycol are common excipients used in both preclinical and commercial formulations. In this paper, the phase diagrams of TPGS and polyethylene...
7.
Wu Y, Dali M, Gupta A, Raghavan K
Pharm Dev Technol
. 2009 Sep;
14(5):556-64.
PMID: 19743950
Drug-excipient compatibility studies lay the foundation for designing a chemically stable formulation for clinical and commercial development. This article describes the investigation of oxidative degradation encountered with compound A (a...
8.
Gu C, Li H, Levons J, Lentz K, Gandhi R, Raghavan K, et al.
Pharm Res
. 2007 Mar;
24(6):1118-30.
PMID: 17385020
Purpose: To develop a statistical model for predicting effect of food on the extent of absorption (area under the curve of time-plasma concentration profile, AUC) of drugs based on physicochemical...
9.
Betigeri S, Thakur A, Raghavan K
Pharm Res
. 2005 Mar;
22(2):310-7.
PMID: 15783080
Purpose: To study the oxidative degradation of drugs using a hydrophilic free radical initiator, 2,2'-Azobis(-amidinopropane) dihydrochloride (AAPH). Methods: AAPH was used as the free radical initiator to study oxidation of...
10.
Gu C, Rao D, Gandhi R, Hilden J, Raghavan K
J Pharm Sci
. 2005 Mar;
94(1):199-208.
PMID: 15761943
A novel multicompartment dissolution system was developed by modifying a conventional six-vessel United States Pharmacopoeia dissolution system to study the dissolution and possible precipitation of poorly soluble weak bases after...